EBS Earnings & Financial Statements
Emergent BioSolutions Inc.
$6.91
$0.00(0.00%)
57
Overall
80
Value
50
Tech
42
Quality
Market Cap
$354.30M
Volume
761.08K
52W Range
$4.36 - $14.06
Target Price
$10.00
EBS earnings and financial statements: Emergent BioSolutions Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
EBS Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $742.90M | $1.04B | $1.05B | $1.08B | $1.79B |
| Cost of revenue | $326.20M | $681.30M | $705.40M | $693.10M | $748.10M |
| Operating income | $100.10M | -$108.70M | -$726.40M | -$170.00M | $352.60M |
| EBITDA | $247.70M | $44.30M | -$496.90M | -$34.30M | $461.50M |
| Net income | $52.60M | -$190.60M | -$760.50M | -$211.60M | $219.50M |
| EPS (diluted) | $0.93 | $-3.60 | $-14.85 | $-4.47 | $4.27 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $1.32B | $1.39B | $1.82B | $3.17B | $2.96B |
| Total liabilities | $796.00M | $906.90M | $1.17B | $1.78B | $1.34B |
| Shareholders’ equity | $522.60M | $482.80M | $649.30M | $1.39B | $1.62B |
| Cash and equivalents | $205.40M | $99.50M | $111.70M | $642.60M | $576.10M |
| Long-term debt | $572.10M | $663.70M | $446.50M | $448.50M | $809.40M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $170.60M | $58.70M | -$206.30M | -$34.10M | $320.20M |
| Capital expenditure | $24.40M | -$15.00M | -$51.60M | -$115.80M | -$224.10M |
| Free cash flow | $156.80M | $35.80M | -$257.90M | -$149.90M | $96.10M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | EBS | $6.91 | 0% | 761.08K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Emergent BioSolutions Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW